HK1169168A1 - Use of dppiv/seprase as a marker for cancer dppiv/seprase - Google Patents

Use of dppiv/seprase as a marker for cancer dppiv/seprase

Info

Publication number
HK1169168A1
HK1169168A1 HK12109860.4A HK12109860A HK1169168A1 HK 1169168 A1 HK1169168 A1 HK 1169168A1 HK 12109860 A HK12109860 A HK 12109860A HK 1169168 A1 HK1169168 A1 HK 1169168A1
Authority
HK
Hong Kong
Prior art keywords
seprase
dppiv
marker
cancer
cancer dppiv
Prior art date
Application number
HK12109860.4A
Other languages
English (en)
Chinese (zh)
Inventor
Lange Magdalena Swiatek-De
Johann Karl
Wolfgang Rollinger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1169168A1 publication Critical patent/HK1169168A1/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
HK12109860.4A 2009-05-04 2012-10-08 Use of dppiv/seprase as a marker for cancer dppiv/seprase HK1169168A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09006097 2009-05-04
PCT/EP2010/002544 WO2010127782A1 (fr) 2009-05-04 2010-04-26 Utilisation du complexe dppiv/séprase comme marqueur du cancer

Publications (1)

Publication Number Publication Date
HK1169168A1 true HK1169168A1 (en) 2013-01-18

Family

ID=40796163

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12109860.4A HK1169168A1 (en) 2009-05-04 2012-10-08 Use of dppiv/seprase as a marker for cancer dppiv/seprase

Country Status (7)

Country Link
EP (1) EP2427772B1 (fr)
JP (1) JP5312684B2 (fr)
CN (1) CN102414565B (fr)
CA (1) CA2760735C (fr)
ES (1) ES2533428T3 (fr)
HK (1) HK1169168A1 (fr)
WO (1) WO2010127782A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2684049A1 (fr) * 2011-03-11 2014-01-15 Roche Diagniostics GmbH Séprase en tant que marqueur pour une maladie pulmonaire obstructive chronique (copd)
CA2826812A1 (fr) * 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Fen1 en tant que marqueur pour une maladie pulmonaire obstructive chronique (copd)
US10226238B2 (en) 2011-09-12 2019-03-12 Creatics Llc Non-invasive methods of detecting target molecules
CN103163303B (zh) * 2012-06-19 2016-02-24 中国医学科学院肿瘤医院 辅助诊断肺腺癌患者的试剂盒
CN103175969B (zh) * 2012-06-19 2015-09-02 中国医学科学院肿瘤医院 辅助诊断肺鳞癌患者的试剂盒
AU2014243704A1 (en) * 2013-03-13 2015-09-10 Creatics Llc Methods and compositions for detecting pancreatic cancer
WO2014190450A1 (fr) * 2013-05-28 2014-12-04 中国医学科学院肿瘤医院 Trousse de réactifs de test facilitant le diagnostic d'un carcinome pulmonaire à cellules squameuses chez un patient
EP2916134B1 (fr) 2014-03-05 2017-08-16 Roche Diagnostics GmbH Utilisation de la séprase pour le diagnostic différentiel de la dyspnée aiguë
US10383956B2 (en) 2014-07-11 2019-08-20 The University Of Tokyo Fluorescent probe for detecting dipeptidyl peptidase IV
JP6750140B2 (ja) * 2014-08-22 2020-09-02 アボット・ラボラトリーズAbbott Laboratories 直腸結腸がんを早期検出するための方法
CA2966660A1 (fr) 2014-11-13 2016-05-19 The Johns Hopkins University Blocage de point de controle et instabilite des microsatellites
CN107326065B (zh) * 2016-04-29 2022-07-29 博尔诚(北京)科技有限公司 一种基因标识物的筛选方法及其应用
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
WO2022007283A1 (fr) * 2020-07-08 2022-01-13 深圳霁因生物医药转化研究院 Kit et méthode de diagnostic d'une maladie associée à une expression de fap anormale, et support de stockage lisible par ordinateur

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
EP1184666A3 (fr) * 2000-08-21 2002-04-10 Roche Diagnostics GmbH Haptènes remplacant des agents hapténylés auxiliaires dans les dosages immunologiques
EP1315829B1 (fr) * 2000-09-09 2010-07-28 The Research Foundation Of State University Of New York Methodes et compositions d'isolation de cellules cancereuses metastatiques, et utilisation correspondante lors de la mesure du potentiel metastatique d'un cancer
BRPI0708900A2 (pt) * 2006-03-13 2011-06-14 Becton Dickinson Co diagnàstico e prognàstico de estados màrbidos associados com dipeptidil peptidases
JP2008118915A (ja) * 2006-11-10 2008-05-29 Kazuto Nishio 胃癌高発現遺伝子特定による胃癌診断および創薬への利用

Also Published As

Publication number Publication date
CN102414565A (zh) 2012-04-11
CA2760735C (fr) 2016-12-06
CN102414565B (zh) 2014-09-24
WO2010127782A1 (fr) 2010-11-11
JP5312684B2 (ja) 2013-10-09
EP2427772B1 (fr) 2015-01-21
JP2012526267A (ja) 2012-10-25
ES2533428T3 (es) 2015-04-10
EP2427772A1 (fr) 2012-03-14
CA2760735A1 (fr) 2010-11-11

Similar Documents

Publication Publication Date Title
HK1169168A1 (en) Use of dppiv/seprase as a marker for cancer dppiv/seprase
HK1166130A1 (en) Use of s-erbb-3 as a marker for cancer s-erbb-3
EP2445343A4 (fr) Promédicaments de composés nh acides
HK1162669A1 (en) Pacap as a marker for cancer pacap
ZA201108131B (en) Dihydroorotate- dehydrogenasee inhibitors as virostatic compounds
AU328687S (en) USB adaptor
GB2474428B (en) Umbilical
SI2432884T1 (sl) Plazmid brez antibiotika
GB2475952B (en) Fifth wheel secondary lock
EP2495561A4 (fr) Marqueur permettant de déterminer la sensibilité à un agent anticancéreux
HK1170566A1 (en) Secernin-1 as a marker for cancer -1
ZA201106972B (en) Pointing agent for stone
ZA201200888B (en) New tumor marker
HK1160218A1 (en) Asc as a marker for lung cancer asc
GB0908071D0 (en) Marker
HK1165204A1 (en) Cybp as a marker of lung cancer cybp
HK1169314A1 (zh) δ-生育酚-碳水化合物作為脫色劑的用途
GB2474751B (en) Transfer wheel markers
GB0905964D0 (en) Marker
IL220316A (en) Mitf as a marker of cancer tendency
EP2250290A4 (fr) Gène pttg1 utilisé comme biomarqueur dans le traitement d un cancer
EP2473679A4 (fr) Marqueur tactile
GB0809689D0 (en) Markers for prostate cancee
GB0920010D0 (en) Markers of pre-eclampsia
PL118678U1 (pl) Długopis